Initial Results of Phase 2/3 Trial of AL102 for Treatment of Desmoid Tumors (DT)


Affiliations:
1. Memorial Sloan Kettering Cancer Center, New York, NY, USA
2. The Royal Marsden NHS Foundation Trust + Institute of Cancer Research, London, UK
3. University of Michigan, Ann Arbor, MI, USA
4. City of Hope Comprehensive Cancer Center, Duarte, CA, USA
5. University of California Los Angeles, Los Angeles, CA, USA
6. Washington University School of Medicine, St. Louis, MO, USA
7. Princess Alexandra Hospital and Icon Cancer Centre, South Brisbane, Australia
8. Massachusetts General Hospital, Boston, MA, USA
9. Peter MacCallum Cancer Centre, Victoria, Australia
10. University of Texas MD Anderson Cancer Center, Houston, TX, USA
11. Thomas Jefferson University, Philadelphia, PA, USA
12. NorthShore University HealthSystem, Evanston, IL, USA
13. Stanford University, Palo Alto, CA, USA
14. Sarcoma Oncology Center, Santa Monica, CA, USA
15. Jefferson City Medical Group, Jefferson City, MO, USA
16. Severance Hospital, Yonsei University, Seoul, South Korea
17. The Christie Hospital, Manchester, UK
18. Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
19. Oregon Health Sciences University, Portland, OR, USA
20. Columbia University, New York, NY, USA
21. Netherlands Cancer Institute, Amsterdam, The Netherlands
22. Ayala Pharmaceuticals, Rehovot, Israel and Northbrook, IL, USA
23. Mannheim University Medical Center, Mannheim, Germany

Background: AL102 is a potent, orally available, selective gamma secretase inhibitor (GSI) under investigation as an antineoplastic agent. GSIs have antitumor activity against DT, including AL101 (2 confirmed PRs >3.5 years and >1 year; 1 stable disease for 1 year). There remains an unmet need for effective systemic therapy in DT, associated with durable tolerability, tumor regression, and symptom improvement.
**Methods:** RINGSIDE is a Phase 2/3 randomized study in patients with progressing DT. Part A (Phase 2) is an open-label part with safety as the primary endpoint. Patients are randomized to three dosing regimens: 1.2 mg QD, 2 mg intermittent BIW (2 days on 5 days off), or 4 mg intermittent BIW. Part B is a Phase 3 double-blind, placebo-controlled study with PFS as primary endpoint. The dose for part B will be determined based on the totality of data collected in part A.

**Results and Conclusions:** Safety, efficacy, PRO, PK, and biomarker results from Part A of the study will be presented at the meeting.